1. Background {#section0005}
=============

Coronavirus infections of humans are mostly restricted to the respiratory tract. The human coronaviruses were first identified in the mid 1960s (HCoV-229E and HCoV-OC43[@bib1], [@bib2], [@bib3]), but in 2003, 2004 and 2005, three new human coronavirus species have been identified (SARS-CoV, HCoV-NL63 and HCoV-HKU1, respectively[@bib4], [@bib5], [@bib6], [@bib7]). HCoV-NL63 was first described in a child with bronchiolitis in Amsterdam, the Netherlands,[@bib6] but it soon turned out that HCoV-NL63 infection occurs frequently in children,[@bib8], [@bib9], [@bib10] is observed around the globe (reviewed in [@bib11]), and infection is associated with croup and acute otitis media.[@bib10], [@bib12]

2. Objectives {#section0010}
=============

The disease burden caused by respiratory viruses is huge in children, which led to the development of vaccines that can be used in young children. For the new respiratory viruses the disease burden is unknown, therefore we determined the burden of disease due to HCoV-NL63 infections in the population-based study (PRI.DE study) on children under the age of 3 with lower respiratory tract infections (LRTI). The PRI.DE study covers 2 years, and children were recruited in the north, east, south and west of Germany at pediatric practices and referral children\'s hospitals.[@bib13] This study design ascertained representation of the German children as 95% of them have a pediatrician, and -- in case of hospitalization -- over 95% of them are referred to a children\'s hospital.

3. Study design {#section0015}
===============

3.1. Participants, materials and laboratory testing {#section0020}
---------------------------------------------------

Paediatric practices (outpatients) and hospitals (inpatients) from Hamburg, Bochum, Freiburg and Dresden participated in the study.[@bib13] Children with clinical signs of apnoea (under the age of 6 months), laryngotracheitis (croup), bronchitis, bronchiolitis, or pneumonia were included in the study. Signs and symptoms were defined according to Denny and Clyde.[@bib14] Recruitment covered the period from November 1999 to October 2001. Nasopharyngeal secretions (NPS) were collected in a standardized manner as described.[@bib13] Of the 3.677 NPS that were collected within the PRI.DE study, half were randomly assigned to this study. The randomization was performed via a program generating random numbers in order to distribute samples equally between 2 different laboratories. The ethics committee of each participating center approved the study protocol and written informed consent was obtained from parents of all children. RNA was extracted and tested for RSV, PIV-1, PIV-2, PIV-3, influenza viruses and HCoV-NL63 by hexaplex PCR and real-time RT-PCR as described.[@bib10] Samples collected in France (winter 2003/2004) and the Netherlands (2002 till 2005) that were screened for HCoV-NL63 were analyzed as described.[@bib6], [@bib15] Furthermore, data from literature were included only for those studies that screened consecutive years in Western Europe and in which each year the sample selection criteria did not change. Thus a year-to-year difference is a reflection of periodicity of infection.

3.2. Incidence calculations {#section0025}
---------------------------

Incidence rates were estimated based on the PRI.DE results,[@bib13] i.e. an incidence of lower respiratory tract infections of 28.7 per 100 children per year seen by a doctor, and using HCoV-NL63 infection rates obtained from our analysis. The PRI.DE population at risk was determined using numbers of well-baby visits which are attended regularly.[@bib16] These figures were used to estimate total numbers of LRTI cases and HCoV-NL63-LRTI cases in the German pediatric population, based on German census data (population size on December 31st, 1999; data from Statistisches Bundesamt, Statistisches Jahrbuch 2001).

3.3. Hospitalization rates {#section0030}
--------------------------

Figures for the total number of hospitalizations in the German pediatric population were determined by applying the observed proportion of HCoV-NL63-related LRTI cases in the PRI.DE study hospitals to the total number of hospitalizations in 1999 in Germany (data from Statistisches Bundesamt, Statistisches Jahrbuch 2002; interpolation of age groups 0--1 year and 1--5 years).

3.4. Confidence intervals {#section0035}
-------------------------

95% confidence intervals (CIs) for incidence rates and hospitalization rates were obtained by calculating exact 97.5% CIs from the binomial distribution for infection rates and combining these with 97.5% CIs for the hospitalization rate due to LRTI or annual LRTI incidence rate.[@bib16]

4. Results {#section0040}
==========

4.1. Burden of disease {#section0045}
----------------------

The PRI.DE study is a prospective population-based study. One can thus calculate the annual incidence rate and the total national disease burden attributable to HCoV-NL63-related LRTIs in children under the age of 3 years. This calculation uses national census data (outpatients) and national hospital statistics (inpatients). In total 1756 PRI.DE samples are included in the present study, representing 48% of the total number of samples that were collected. To confirm whether the HCoV-NL63-tested samples were representative for the entire PRI.DE study (which comprised 3677 children), we checked collection dates, study region, age, male/female distribution, diagnosis, virus detection and determined that in none of these categories there was any bias in sample selection (shown in [Table 1](#tbl1){ref-type="table"}, [Table 2](#tbl2){ref-type="table"} ). Of the 1756 children, 685 visited the outpatient clinic, and 1071 were hospitalized.Table 1Comparison of demographic, clinical and virological characteristics of PRI.DE study population and the randomly selected subgroup of the present HCoV-NL63 study.CategoryPRI.DE study patientsHCoV-NL63-tested patients (%)HCoV-NL63-positive patients (%)Study region Freiburg1350657 (49%)24 (3.6%) Dresden995490 (49%)24 (4.9%) Bochum467208 (44%)6 (2.9%) Hamburg865401 (46%)15 (3.7%)  Age 0 year1989936 (47%)31 (3.3%) 1 year1115535 (48%)25 (4.7%) 2 years569284 (50%)13 (4.6%)  M/F Male21331015 (48%)43 (4.2%) Female1533734 (48%)26 (3.5%)  Diagnosis Croup290134 (46%)18 (13.4%)[\*](#tbl1fn1){ref-type="table-fn"} Bronchitis851423 (50%)18 (4.3%) Bronchiolitis or wheezing bronchitis2054965 (47%)31 (3.2%) Pneumonia853398 (47%)8 (2.0%) Apnoea8037 (46%)0 (0.0%)  Virus detected RSV A/B1247545 (43%)28 (5.1%) PIV 1/2/3377194 (51%)6 (3.1%) INF A/B14163 (45%)0 (0.0%)[^1]Table 2HCoV-NL63 analysis on PRI.DE samples.Month of samplingPRI.DE samples collectedHCoV-NL63 study patients (% of PRI.DE study)Nr (%) of samples positive for HCoV-NL63November 199916269 (43%)1 (1.4%)December 199921390 (42%)1 (1.1%)January 2000307130 (42%)3 (2.3%)February 2000292139 (47%)3 (2.2%)March 2000347156 (45%)0 (0%)April 200015173 (48%)2 (2.7%)May 20008341 (49%)0 (0%)June 20003615 (42%)0 (0%)July 20002813 (46%)0 (0%)August 20004420 (45%)0 (0%)September 20008240 (49%)0 (0%)October 200010351 (50%)0 (0%)November 2000215108 (50%)9 (8.3%)December 2000279134 (48%)18 (13.4%)January 2001344171 (49%)12 (7.0%)February 2001227114 (50%)13 (11.4%)March 2001205107 (52%)4 (3.7%)April 200114875 (51%)0 (0%)May 20019541 (43%)1 (2.4%)June 20016531 (48%)0 (0%)July 20014524 (53%)0 (0%)August 20012211 (50%)0 (0%)September 20017335 (48%)1 (2.9%)October 200111168 (61%)1 (1.5%)

In total we detected 69 HCoV-NL63 infections (3.9%). Of these, 38 were children visiting the outpatient clinic (5.5% of outpatients) and 31 children were hospitalized (2.9% of all hospitalized patients). Similar to what was published previously[@bib10] a high frequency of croup was noted in the HCoV-NL63 infected children (26.1% of all HCoV-NL63 positives, *p*  \< 0.0001 two-sided Fisher\'s exact test).

The peak of infection was centered around the winter months of each year ([Fig. 1](#fig1){ref-type="fig"} ). When we include all HCoV-NL63 infections (*n*  = 69) to calculate the burden of disease, a total of 16 visits to the physician per 1000 children per year were calculated, corresponding to 37,841 visits to a physician per year in Germany. The hospitalization rate is 85 per 100,000 children per year, corresponding to 2022 hospitalizations per year in Germany. However, during double infections it is debatable whether one or the combination of the two viruses causes the disease encountered. Double infections with HCoV-NL63 and a second respiratory virus were frequently found (49.3%). Furthermore we observed a very strong association between a high HCoV-NL63 viral load and single infections, and in case of double infections the viral load was low (*p*  \< 0.0001, Wilcoxon\'s two sample test).[@bib10] To ascertain that the disease burden is calculated for HCoV-NL63 infections only and not influenced by infections with another respiratory virus we included only those infections which were not accompanied by a second respiratory virus (*n*  = 35). Furthermore we included merely HCoV-NL63 infections with high viral load, which was arbitrarily defined as samples with more than 10,000 copies per ml (*n*  = 25). Using these restrictions we calculated that the annual incidence of HCoV-NL63 infection was 7 per 1000 children per year (95% confidence interval (CI) 3--13 per 1000 children per year), reflecting an absolute number of 16,929 visits to the physician in Germany per year (95% CI: 7255--31,440). The estimated hospitalization rate due to HCoV-NL63 alone is 22 per 100,000 children (95% CI: 7--49 per 100,000 children per year). This number reflects 522 children in Germany per year (95% CI: 166--1163), which is a conservative estimate.Fig. 1Percentage HCoV-NL63 positive samples in the PRI.DE study.

4.2. Periodicity of infection {#section0050}
-----------------------------

The winter season is the preferred season for infection by HCoV-NL63, yet large year-to-year differences in frequency is apparent. As shown in [Fig. 1](#fig1){ref-type="fig"}, infection by HCoV-NL63 is limited to a small percentage in the first year of the study, whereas in the winter of 2000/01 the frequency reaches levels above 10%. This indicates that there is an inter-epidemic period,[@bib17] but it cannot be determined whether HCoV-NL63 peaks every 2, 3 or more years. To investigate this periodicity and the inter-epidemic period we combined literature data and performed additional screening for HCoV-NL63 in hospitalized patients and outpatients with acute respiratory infections in the Netherlands and France during the period 2001 till 2005. A higher frequency of infection in the winters of 2000/01, 2002/03 and 2004/05 and less infections in the 2001/02 and 2003/04 winter was observed ([Table 3](#tbl3){ref-type="table"} and [@bib15], [@bib18], [@bib19]), indicating that the frequency is high every other year. To verify whether the inter-epidemic period is 2 years we combined all our data and the published data on HCoV-NL63 screenings during 2 or more consecutive years in Western Europe[@bib6], [@bib19], [@bib20], [@bib21], [@bib22], [@bib23] and confirmed that in 2000/2001, 2002/2003 and 2004/2005 significantly higher infection rates are observed compared to 1999/2000, 2001/2002 and 2003/2004 (combined rates 4.5% vs 1.5%, *p*  \< 0.0001, Chi-square test, [Fig. 2](#fig2){ref-type="fig"} ).Table 3Overview of HCoV-NL63 screening in Western European studies covering 2 or more consecutive years.CountryYears tested[a](#tbl3fn1){ref-type="table-fn"}Samples testedSamples positivePercentage positiveReferenceThe Netherlands20018544.71%[@bib19]20025400.00%[@bib19]200357891.56%[@bib6], this study20044000.00%[@bib6], this study200525862.33%[@bib6], this study  Belgium200323362.58%[@bib22]20047011.43%[@bib22]  Switzerland20002214.55%[@bib21]200128517.86%[@bib21]20021000.00%[@bib21]20031600.00%[@bib21]20042214.55%[@bib21]20052229.09%[@bib21]2006200.00%[@bib21]  Germany2000726101.38%This study2001916576.22%This study200211421.75%This study  Sweden200411610.86%[@bib23]20051061110.38%[@bib23]  France2003300289.33%[@bib18]200420042.00%This study20051002333.29%[@bib15][^2]Fig. 2Percentage HCoV-NL63 positive samples in Western Europe, the included studies are described in [Table 3](#tbl3){ref-type="table"}. A year is defined from August to July. \*: significantly higher percentage compared to years 99/00, 01/02 and 03/04, *p* \< 0.0001, Chi-square test.

We found no significant differences when comparing 1999/2000, 2001/2002 and 2003/2004 (rates 1.5%/1.1%/1.6%, *p*  = 0.92, Chi-square test with 2df), but modest differences were noticeable when comparing 2000/2001, 2002/2003 and 2004/2005 (rates 6.4%/3.8%/3.8%, *p*  = 0.003, Chi-square test with 2df).

5. Discussion {#section0055}
=============

In Germany paediatricians are available for all children and they are consulted instead of general practitioners for primary care. Therefore, sampling in paediatric practices provides the opportunity to collect a representative patient set that reflects the population of German children that are ill but not hospitalized. Most studies that have looked at the frequency of HCoV-NL63 infection in patients with respiratory infections have focused exclusively at hospitalized patients. In the PRI.DE study it is possible to investigate the frequency of infection in both groups: those hospitalized and those visiting the paediatric clinic (outpatients). In a previous study we noticed that HCoV-NL63 infection is observed more frequently in outpatients,[@bib10] and here we calculated that it reflects almost 17,000 visits to the paediatrician each year in Germany, whereas less than 600 children under the age of 3 years need to be hospitalized.

There are only 2 previous studies that calculated the incidence of HCoV-NL63 infection, one from Hong Kong and one from Nashville, USA.[@bib12], [@bib24] The Hong Kong study noticed high numbers of hospitalizations due to HCoV-NL63 infection (210 hospital admissions per 100,000 children ≤6 years of age) whereas we estimate 22 hospitalizations per 100,000 children below the age of 3. The difference in age of the test populations is unlikely to explain the difference. We think that other reasons are more significant. In the Hong Kong study all HCoV-NL63-children were included regardless of the viral load in the NPA, or the presence of a second infection. Furthermore, only a single year was monitored in Hong Kong, and we noticed that the incidence of HCoV-NL63 displays year-to-year differences with a 3--4 times higher rate in uneven winters in Western Europe. We did not include any double infections and HCoV-NL63 infections with low viral load, to diminish the chance that children who are ill due to another respiratory virus infection are counted. In addition, it cannot be ruled out that we even missed some double infections since our samples were not tested for all respiratory pathogens (e.g. hMPV, human bocavirus, and rhinoviruses).

The Nashville study included children with LRTI from several years and a high incidence of HCoV-NL63 in the 6--23 months age group was observed: 12.3 HCoV-NL63 associated LRTIs per 1000 children, although the number of samples that were tested was small (only 5 positives of the 119 samples analyzed).[@bib12] These data are in concordance with our findings as most of the children in their study were not hospitalized, therefore the incidence numbers are comparable to what we noticed for outpatients (7 per 1000 children).

The periodicity of infection that we observed is not unexpected. Already in the mid-1970s Monto & Lim described high infection rates with HCoV-OC43 in the years 1966, 1968 and 1969, but low numbers in 1967.[@bib25] Actually many childhood diseases tend to vary in frequency between years. These oscillations are often of a regular nature, tending to rise as a function of susceptible persons.[@bib17] We noticed that the inter-epidemic period is 2 years with 2000/2001, 2002/2003 and 2004/2005 being strong years.

In our study we tested for HCoV-NL63. Taking into account that infection by HCoV-OC43, HCoV-229E, and HCoV-HKU1 can also result in LRTI,[@bib26], [@bib27] the incidence numbers for coronavirus infection are probably several folds higher than the numbers we present for just HCoV-NL63 infections. It would be of great interest to determine the incidence of the other coronaviruses in the sample set tested for HCoV-NL63.
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[^1]: *p* \< 0.000 two-sided Fisher\'s exact test.

[^2]: A year is defined from August to July, e.g. year 2000 is the period between August 1999 till July 2000.
